In vitro evaluation of GL331's cancer cell killing and apoptosis- inducing activity in combination with other chemotherapeutic agents

Apoptosis

Volumn 5, Issue 1, 2000, Pages 79-85

  Huang, Tze Sing ^b   Shu, Chih Hung ^a   Lee, Chun Chung ^c   Chen, Li Tzong ^c   Whang Peng, Jacqueline ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NONE

Author keywords

Apoptosis; Combination chemotherapy; GL331; VP 16

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GL 331; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG CROSS REACTIVITY; FLOW CYTOMETRY; LABELING INDEX; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETOPOSIDE; FLUOROURACIL; NASOPHARYNGEAL NEOPLASMS; TOXICITY TESTS; TUMOR CELLS, CULTURED;

EID: 0034018817     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009693811093     Document Type: Article

References (13)

1. Whang-Peng J, Huang T-S. New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J Intern Med Taiwan 1997; 8: 6-11.
2. Huang T-S, Shu C-H, Shih Y-L, et al. J. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett 1996; 110: 77-85.
3. Huang T-S, Lee C-C, Chao Y, et al. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut Res 1999; 16: 997-1002.
4. Kuo M-L, Shen S-C, Yang C-H, Chuang S-E, Cheng A-L, Huang T-S. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene 1998; 17: 2225-2234.
5. Huang T-S, Yang WK, Whang-Peng J. GL331-induced disruption of cyclin B1/CDC 2 complex and inhibition of CDC 2 kinase activity. Apoptosis 1996; 1: 213-217.
6. Huang T-S, Shu C-H, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 1997; 57: 2974-2978.
7. Sullivan DM, Chow K-C, Ross WE. Topoisomerase II mediated mechanisms of drug resistance. In: Kessel D, ed. Resistance to Antineoplastic Drugs. Boca Raton, FL: CRC Press, 1989: 281-292.
8. Lin C-T, Chan W-Y, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993; 68: 716-727.
9. Shu C-H, Yang WK, Huang T-S. Increased cyclin B1/CDC 2 kinase activity and phosphorylation of Bcl-2 associated with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 1996; 1: 141-146.
10. Overbeeke R, Steffens-Nakken H, Vermes I, Reutelingsperger C, Haanen C. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 1998; 3: 115-121.
11. 1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 1996; 13: 625-632.
12. Friedland ML. Combination chemotherapy. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins, 1992: 90-95.
13. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. Choice of drugs for cancer chemotherapy. In: The Anticancer Drugs. New York: Oxford University Press, 1994: 235-246.